|
|
|
|
Showcase Stocks For: 06-Feb to 10-Feb |
|
Company Name: |
QuinStreet Inc (Public, NASDAQ:QNST) |
|
Symbol: |
QNST |
|
|
Detail Quote
Chart |
|
Company Snapshot: |
|
|
QuinStreet, Inc. (QuinStreet) is engaged in vertical marketing and media on the Internet. The Company operates in two segments: Direct Marketing Services (DMS) and Direct Selling Services (DSS). The DMS segment derives substantially all of its revenue from fees earned through the delivery of qualified leads or paid clicks. The DSS segment derives substantially all of its revenue from sale of direct selling services through a hosted solution. DSS revenue comprises set-up and professional services fees and usage fees. On September 14, 2009, the Company acquired 100% of HSH Associates Financial Publishers (HSH), an online marketing business. Also, in July 2010, it acquired the Website business Insurance.com from Insurance.com Group, Inc., or Insurance.com, an Ohio-based online insurance business. In November 2010, it acquired CarInsurance.com. In September 2011, the Company acquired IT Business Edge. In November 2011, the Company announced the acquisition of ConsumerismCommentary.com. |
|
|
|
Company Name: |
Zalicus, Inc. (Public, NASDAQ:ZLCS) |
|
Symbol: |
ZLCS |
|
|
Detail Quote
Chart |
|
Company Snapshot: |
|
|
Zalicus Inc. (Zalicus), formerly CombinatoRx, is a biopharmaceutical company developing drug candidates with a focus on the treatment of pain and inflammation. The Company has devoted substantially all of its resources to the development of its drug discovery technologies and the research and development of its drug candidates, including conducting preclinical and clinical trials and seeking intellectual property protection for its technology and product candidates. The Company operates in two geographic segments: the United States and Canada. On March 1, 2010, the United States Food and Drug Administration (FDA), approved the New Drug Application for Exalgo (hydromorphone HCl) extended-release tablets, for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time. |
|
|
|
|
|
|
US
